Calibrate vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 35)
Calibrate logo

Calibrate

EmergingHealthTech

Metabolic Health Platform

Metabolic health company delivering one-year GLP-1 programs with semaglutide or tirzepatide plus behavioral coaching, nutrition, and activity guidance via physician-supervised telehealth.

AI VisibilityBeta
Overall Score
D35
Category Rank
#560 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
36
Gemini
40

About

Calibrate is a metabolic health company that delivers a one-year weight loss program combining GLP-1 receptor agonist medications — including semaglutide and tirzepatide — with behavioral coaching, food education, sleep guidance, and activity programming through a telehealth platform. The program's clinical foundation differentiates it from consumer weight loss apps and traditional diet programs by centering medication management under physician supervision as the primary intervention, with lifestyle coaching structured to support long-term habit change alongside pharmaceutical treatment. Calibrate's approach reflects the clinical consensus that obesity is a chronic metabolic disease requiring medical treatment rather than a lifestyle choice addressable through willpower alone.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

35
Overall Score
90
#560
Category Rank
#2
76
AI Consensus
83
stable
Trend
stable
39
ChatGPT
92
36
Perplexity
93
40
Gemini
89
30
Claude
96
34
Grok
95

Key Details

Category
Metabolic Health Platform
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Calibrate
Metabolic Health Platform

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.